within Pharmacolibrary.Drugs.ATC.N;

model N07XX12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 3.01 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Patisiran is an RNA interference (RNAi) therapeutic agent approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It works by silencing the transthyretin (TTR) gene, thereby reducing the production of mutant and wild-type TTR protein which forms amyloid deposits.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with hereditary transthyretin-mediated amyloidosis; values pertain to patisiran lipid nanoparticle (LNP) formulation after intravenous administration.</p><h4>References</h4><ol><li><p>Badri, P, et al., &amp; Robbie, GJ (2023). Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation. <i>Clinical pharmacokinetics</i> 62(10) 1509–1522. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01292-w&quot;>10.1007/s40262-023-01292-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37639169/&quot;>https://pubmed.ncbi.nlm.nih.gov/37639169</a></p></li><li><p>Zhang, X, et al., &amp; Robbie, GJ (2020). Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis. <i>Journal of clinical pharmacology</i> 60(1) 37–49. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1480&quot;>10.1002/jcph.1480</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31322739/&quot;>https://pubmed.ncbi.nlm.nih.gov/31322739</a></p></li><li><p>Zhang, X, et al., &amp; Robbie, GJ (2020). Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis. <i>Journal of clinical pharmacology</i> 60(5) 573–585. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1553&quot;>10.1002/jcph.1553</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31777097/&quot;>https://pubmed.ncbi.nlm.nih.gov/31777097</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX12;
